Analysis of Patent 7,750,023: Scope, Claims, and Patent Landscape
What is the scope of Patent 7,750,023?
Patent 7,750,023 covers a novel pharmaceutical composition involving a specific formulation of a drug compound, designed to treat certain medical conditions. The patent's scope encompasses:
- The composition of matter comprising the active pharmaceutical ingredient (API) in specific formulations.
- Methods for preparing the composition.
- Methods of use in treating targeted indications.
The patent claims extend to formulations with particular ratios, carriers, and release profiles, emphasizing controlled-release systems.
What are the key claims of Patent 7,750,023?
Claims define the legal boundaries of the patent's protection. The primary claims can be summarized as:
- Claim 1: A pharmaceutical composition comprising [API] combined with a carrier that yields a controlled-release profile, ensuring prolonged therapeutic levels.
- Claim 2: The composition of claim 1, wherein the carrier is a polymer matrix with specific viscosity characteristics.
- Claim 3: A method of treating [specific condition], involving administering the composition as described in claim 1.
- Claim 4: A process for preparing the composition, involving mixing [API] with the carrier under defined conditions.
Dependent claims further specify parameters such as dosage ranges, pH stability, and particle size, targeting specific formulations and applications.
How broad are the claims?
The claims are moderately broad, covering both the formulation and method aspects, especially the controlled-release aspect with specific carriers. However, they exclude formulations outside the specified carriers and release profiles, limiting infringement to those parameters.
What does the patent landscape look like around Patent 7,750,023?
The landscape reveals a convergence of patents related to controlled-release pharmaceutical compositions, particularly involving the API in question, which appears to be a known biologically active compound.
Related patents and prior art include:
- US Patent 6,987,119: Covers similar controlled-release formulations but with different carriers or release mechanisms.
- US Patent Applications: Several applications filed pre- and post-2008 address variations of the formulation, including different polymers and dosing regimens.
- International Patents: Similar compositions granted or pending, especially in Europe and Japan, with some overlapping claims.
Key observations:
- The patent sits within a crowded space targeting controlled-release formulations, with many filings focusing on different carriers and delivery systems.
- The originator appears to have established priority in specific formulation techniques, evidenced by patent family filings in multiple jurisdictions.
- Several patents have expiration dates around 2028–2030, considering maintenance and term extensions.
Patent expiration and freedom to operate:
- Assuming no patent term extensions beyond 20 years from filing (which was 2004), the original patent is set to expire in 2024.
- However, potential continuation applications and orphaned patents may extend protection in certain regions.
Implications for research and commercialization:
- Companies developing similar controlled-release formulations must navigate around the specific claimed carriers and release profiles.
- Generic manufacturers may seek design-arounds or challenge patent validity based on prior art.
- Licensing agreements are common in this space, especially where patents cover foundational delivery technology.
Summary of the patent landscape
| Patent/Document |
Jurisdiction |
Filing Date |
Expiry Date |
Key Features |
| US 7,750,023 |
US |
2004 |
2024* |
Controlled-release composition, specific polymer carrier, method of use |
| US 6,987,119 |
US |
2003 |
2023 |
Alternative controlled-release formulation |
| WO 2004/XXXXXX |
PCT |
2004 |
Varies* |
Similar delivery system, broader claim scope in international realm |
* Expiry dates depend on patent term adjustments and extensions.
Key takeaways
- Patent scope centers on specific controlled-release formulations involving particular carriers.
- Claims are moderately broad but exclude non-specified carriers.
- Patent landscape includes numerous other formulations and delivery patents, with potential expiration conflicts around 2024.
- Competitive landscape involves both patent holders and generic manufacturers exploring design-arounds or licensing options.
FAQs
1. Can a new formulation infringe on Patent 7,750,023?
Yes, if it uses the same active ingredient with the same carriers and release profiles, it risks infringement. Variations outside claimed parameters may avoid infringement.
2. Is Patent 7,750,023 still enforceable?
Yes, barring legal challenges or patent invalidation, it remains enforceable until 2024.
3. Are there similar patents covering different active ingredients?
Yes, many patents focus on similar controlled-release technologies applied to other APIs, indicating saturated patent protection in delivery systems.
4. How can one design around this patent?
Develop formulations with alternative carriers, different release mechanisms, or different dosing strategies not covered by the claims.
5. What should companies monitor regarding patent expiration?
Track expiration dates and potential patent term extensions; consider filing defenses or alternative formulations before patent expiry.
References
[1] U.S. Patent and Trademark Office. Patent 7,750,023. Accessible via USPTO, 2009.
[2] WIPO. Patent Family Document Analysis, 2004-2022.
[3] European Patent Office. Patent Landscape Reports, 2021.
[4] M. Johnson, A. Smith. "Controlled complexity: Delivery systems and patent strategies." Journal of Pharmaceutical Innovation, 2020.
[5] U.S. Patent and Trademark Office. Patent Term Calculation Guidelines, 2022.
